Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
BRUCE L. LEVINE · UNIVERSITY OF PENNSYLVANIA · 2019 · $812,276 — SUMMARY CORE B: GMP CELL and RNA MANUFACTURING Core B is the Clinical Cell and Vaccine Production Facility (CVPF). The CVPF is a Foundation for the Accreditation of Cellular Therapy (FACT)-accredited, Good Manufacturing Practices (GMP) compliant cell and RNA manufacturing facility. This facility sup…
Kathryn M. Anastos · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2019 · $70,819 — Investigations of HPV related malignancies are heavily dependent on laboratory testing, both to measure the outcomes (cancer, pre-cancer, intraepithelial neoplasia) and to define the possible predictors (e.g. high-risk HPV types). Several new molecular diagnostic tests are becoming available, includ…
Barton F. Haynes · DUKE UNIVERSITY · 2019 · $274,720 — The Administrative Core will coordinate the scientific and administrative activities of this IPCAVD Program, ensuring that the Projects and Cores function well together. In particular, it will be responsible for managing the program's financial management, program management, and coordinating Projec…
Barton F. Haynes · DUKE UNIVERSITY · 2019 · $727,666 — The overall goal of the Animal Models Core is to support all programs of the IPCAVD by performing immunization studies in CH58 unmutated common ancestor (UCA) VH + VL knock-in (KI) mice and rhesus macaques, with ALVAC-C vCP2438 prime and modified mRNA encoding trivalent mosaic gp120s for induction o…
Thomas Denny · DUKE UNIVERSITY · 2019 · $1,625,932 — HIV vaccine candidates entering into clinical testing generally fall into three categories: 1) recombinant envelope (Env) protein immunogens, 2) viral vectors, and 3) plasmid DNA. Numerous vaccine Env designs are being tested in clinical trials. Likewise, numerous HIV vaccine inserts, such as mosaic…
YANG XU · LUNA INNOVATIONS, INC. · 2019 · $1,999,997 — RNA-based vaccines and therapeutics have emerged as great promise for HIV prevention and treatment, respectively. However, many obstacles still need to be overcome, in particular RNA instability, manufacturing problems, and clinically relevant delivery mechanisms of RNA into target cells. RNA vaccin…
AMIT KHANDHAR · PAI LIFE SCIENCES, INC. · 2019 · $299,184 — Effective Targeted Delivery of RNA-based Vaccines and Therapeutics: RNA-based vaccines and therapeutics have emerged as great promise for HIV prevention and treatment, respectively. However, many obstacles still need to be overcome, in particular RNA instability, manufacturing problems, and clinica…
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2019 · $880,342 — PROJECT SUMMARY A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). Here, we propose to leverage three recent discoveries from our groups to generate novel envelope (Env) immunogens that target the V1V2 region of the trimer…
Harvey Michael Friedman · UNIVERSITY OF PENNSYLVANIA · 2019 · $818,356 — Abstract A vaccine for prevention of genital herpes is a high public health priority. Herpes vaccines that performed well in rodents have not protected humans; therefore, novel approaches are needed. We propose the following: 1) Set a much higher bar for vaccine efficacy in animal models than used p…
CHRISTOPHER A BENEDICT · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2019 · $720,659 — Summary Cytomegalovirus (CMV, a b-herpesvirus) establishes a persistent infection that is endemic in humans and mice. CMV causes acute clinical disease only if immunity is naïve or compromised, exemplifying how coevolution with its host over millennia has resulted in a largely non-pathogenic détente…
Elias Sayour · UNIVERSITY OF FLORIDA · 2019 · $158,188 — Abstract: I am now in my first faculty position as an Assistant Professor of Neurosurgery and Pediatrics at the University of Florida. I completed a T32 NIH fellowship at Duke University in Cancer Biology and Developmental Therapeutics before accepting a junior faculty position at the University of …
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2019 · $640,818 — ABSTRACT Influenza virus is one of the most important human infectious diseases. The influenza mortality is estimated to be approximately 650,000 per year worldwide, in addition, occasional global pandemics can infect up to 20- 40% of the world's population. Licensed influenza virus vaccines require…
BRUNO DE BEZERRIL ANDRADE · VANDERBILT UNIVERSITY MEDICAL CENTER · 2019 · $726,648 — PROJECT SUMMARY Recent studies from our group have reported a peripheral blood correlate of risk (COR) transcriptional signature that identified individuals with incipient (asymptomatic) TB who progressed to active (symptomatic) TB disease within 12 months. We have also identified human genetic poly…
JOHN N GALGIANI · UNIVERSITY OF ARIZONA · 2019 · $579,122 — Project Summary Coccidioidomycosis (Valley Fever) is a serious public health problem for the Southwestern United States and all who visit there. A small proportion of infections result in progressive, debilitating, even life-threatening illness (disseminated coccidioidomycosis or DCM). All evidence …
Edward N Janoff · VA EASTERN COLORADO HEALTH CARE SYSTEM · 2019 — 7. Project Summary/Abstract Both advancing age and HIV-1 infection are associated with an increased frequency of infection, such as those due to Streptococcus pneumoniae, and a higher rate of complications and death with these infections. Vaccines are available to prevent a number of infections comm…
Alexander Bukreyev · UNIVERSITY OF TEXAS MED BR GALVESTON · 2019 · $825,853 — PROJECT SUMMARY/ABSTRACT The Marburg virus (MARV) and Ravn virus (RAVV), which both belong to the genus Marburgvirus of the family Filoviridae, cause the severe disease in humans, with case fatality rates up to 90%. There are no licensed vaccines against marburgviruses. Clinical trials of vaccine ca…
Kimberly D. Klonowski · UNIVERSITY OF GEORGIA · 2019 · $225,625 — Abstract Identifying the mechanisms that regulate CD8 T cell responses is critical for improving anti-viral and anti-tumor vaccine efficacy and is currently an area of intense investigation due to the profound implications for improving human health. The goal of this application is to determine the …
Kristyn Rene Aalto · ORLANCE, INC. · 2019 · $298,613 — Gene gun delivery of DNA vaccines, also known as particle mediated epidermal delivery or PMED, delivers DNA vaccines coated onto 1 micron sized gold particles directly into cells of the epidermis. It achieves pain-free delivery, is considerably more efficient than electroporation or other DNA vaccin…
Toni Darville · UNIV OF NORTH CAROLINA CHAPEL HILL · 2019 · $808,098 — DESCRIPTION (provided by applicant): Chlamydia trachomatis infection is the leading cause of infertility and ectopic pregnancy in women. Infection is often asymptomatic, leading to lack of detection, increased risk for disease and delay in treatment. Although antibiotic therapy eliminates infec…
TORU TAKIMOTO · UNIVERSITY OF ROCHESTER · 2019 · $385,000 — Virus infection induces a wide range of host defense mechanisms, such as the innate immune response and inflammation. Some viruses express accessory proteins to induce general shutoff of host protein synthesis, which is considered to be one of the major viral strategies to counteract host antiviral …